MAXCYTE INC. - COMMON

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

13 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

06 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

31 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Cynthia Collins to its Board of Directors

15 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

11 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

10 Oct 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

16 Sep 2024 02:00:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

05 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

06 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

09 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

29 May 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

22 May 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

07 May 2024 16:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

10 Apr 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

02 Apr 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

12 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

04 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

09 Feb 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

30 Jan 2024 08:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

23 Jan 2024 08:05:00 By Nasdaq GlobeNewswire